Details of the Drug Combination

General Information of Drug Combination (ID: DC6J2FO)

Drug Combination Name
Gemcitabine Imatinib
Indication
Disease Entry Status REF
Advanced Pancreatic Cancer Phase 1 [1]
Component Drugs Gemcitabine   DMSE3I7 Imatinib   DM7RJXL
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Gemcitabine
Disease Entry ICD 11 Status REF
Anterior urethra cancer N.A. Approved [2]
Biliary tract cancer 2C17 Approved [2]
Carcinoma 2A00-2F9Z Approved [2]
Cervical cancer 2C77.0 Approved [2]
Cholangiocarcinoma 2C12.10 Approved [2]
Fallopian tube neoplasm N.A. Approved [2]
Gallbladder carcinoma N.A. Approved [2]
Leiomyosarcoma 2B58 Approved [2]
Leukemia N.A. Approved [2]
Lung cancer 2C25.0 Approved [2]
MALT lymphoma N.A. Approved [2]
Nodal marginal zone lymphoma 2A85.0 Approved [2]
Non-small-cell lung cancer 2C25 Approved [3]
Ovarian disorder N.A. Approved [2]
Ovarian neoplasm N.A. Approved [2]
Pancreatic adenocarcinoma N.A. Approved [2]
Pancreatic ductal carcinoma 2C10.0 Approved [2]
Pancreatic tumour 2C10 Approved [2]
Posterior urethra cancer N.A. Approved [2]
Recurrent adult burkitt lymphoma 2A85.6 Approved [2]
Solid tumour/cancer 2A00-2F9Z Approved [4]
Splenic marginal zone lymphoma N.A. Approved [2]
Urethral cancer 2C93 Approved [2]
Urinary bladder neoplasm N.A. Approved [2]
Middle East Respiratory Syndrome (MERS) 1D64 Preclinical [5]
Severe acute respiratory syndrome (SARS) 1D65 Preclinical [5]
Colon cancer 2B90.Z Investigative [2]
Gemcitabine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Ribonucleoside-diphosphate reductase M2 (RRM2) TTBWDI0 RIR2_HUMAN Modulator [18]
------------------------------------------------------------------------------------
Gemcitabine Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [19]
Multidrug resistance-associated protein 5 (ABCC5) DTYVM24 MRP5_HUMAN Substrate [20]
Concentrative nucleoside transporter 1 (SLC28A1) DT0EQPW S28A1_HUMAN Substrate [21]
------------------------------------------------------------------------------------
Gemcitabine Interacts with 5 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytidine aminohydrolase (CDA) DEKEDRC CDD_HUMAN Metabolism [22]
Uridine/cytidine monophosphate kinase (UMPK) DEMPH4I KCY_HUMAN Metabolism [23]
Cytidine deaminase (cdd) DETX3A5 CDD_ECOLI Metabolism [24]
Cytidine deaminase (cdd) DEFVABT CDD_KLEP7 Metabolism [24]
Cytidine deaminase (cdd) DEYILK4 E0TLJ6_MYCHH Metabolism [25]
------------------------------------------------------------------------------------
Gemcitabine Interacts with 244 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytidine deaminase (CDA) OT3HXP6N CDD_HUMAN Affects Response To Substance [16]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Expression [26]
Ribonucleoside-diphosphate reductase subunit M2 (RRM2) OTOB6J6R RIR2_HUMAN Affects Response To Substance [17]
Ribonucleoside-diphosphate reductase large subunit (RRM1) OTXGQOR9 RIR1_HUMAN Affects Response To Substance [17]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [27]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Decreases Expression [28]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [29]
NF-kappa-B inhibitor epsilon (NFKBIE) OTLAYEL9 IKBE_HUMAN Affects Expression [12]
Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B) OTQ4W7MT TR11B_HUMAN Increases Expression [12]
Stearoyl-CoA desaturase (SCD) OTB1073G SCD_HUMAN Increases Expression [12]
1-acyl-sn-glycerol-3-phosphate acyltransferase beta (AGPAT2) OT5I4Y9K PLCB_HUMAN Decreases Expression [12]
Insulin-induced gene 1 protein (INSIG1) OTZF5X1D INSI1_HUMAN Increases Expression [12]
E3 ubiquitin-protein ligase Praja-2 (PJA2) OT45TMC4 PJA2_HUMAN Increases Expression [12]
Interleukin-1 receptor-associated kinase-like 2 (IRAK2) OT6Y1QZN IRAK2_HUMAN Increases Expression [12]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Expression [12]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like (BNIP3L) OTJKOMXE BNI3L_HUMAN Increases Expression [12]
Heterogeneous nuclear ribonucleoprotein Q (SYNCRIP) OTRNDZXB HNRPQ_HUMAN Decreases Expression [12]
Melanoma-associated antigen C1 (MAGEC1) OTHMFHH8 MAGC1_HUMAN Increases Expression [12]
Liprin-alpha-4 (PPFIA4) OTWXG0DO LIPA4_HUMAN Increases Expression [12]
Transcription factor Maf (MAF) OT1GR3IZ MAF_HUMAN Increases Expression [12]
Protein phosphatase 1 regulatory subunit 15A (PPP1R15A) OTYG179K PR15A_HUMAN Increases Expression [12]
Krueppel-like factor 8 (KLF8) OTUC5CDB KLF8_HUMAN Increases Expression [12]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Increases Expression [12]
Fibrinogen gamma chain (FGG) OT5BJSEX FIBG_HUMAN Affects Expression [12]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases Expression [12]
Keratin, type II cytoskeletal 8 (KRT8) OTTM4X11 K2C8_HUMAN Decreases Expression [12]
Growth-regulated alpha protein (CXCL1) OT3WCTZV GROA_HUMAN Increases Expression [12]
Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) OTXOQDSG IFIT1_HUMAN Increases Expression [12]
Transcriptional activator Myb (MYB) OTJH64IV MYB_HUMAN Increases Expression [12]
Osteopontin (SPP1) OTJGC23Y OSTP_HUMAN Increases Expression [12]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Increases Expression [12]
Solute carrier family 2, facilitated glucose transporter member 3 (SLC2A3) OT2HZK5M GTR3_HUMAN Increases Expression [12]
Creatine kinase B-type (CKB) OTUCKOTT KCRB_HUMAN Decreases Expression [12]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Increases Expression [12]
Homeobox protein Hox-B2 (HOXB2) OTTD6HMV HXB2_HUMAN Increases Expression [12]
Fos-related antigen 2 (FOSL2) OT3MT9HJ FOSL2_HUMAN Decreases Expression [12]
Methylated-DNA--protein-cysteine methyltransferase (MGMT) OT40A9WH MGMT_HUMAN Decreases Expression [12]
CCAAT/enhancer-binding protein beta (CEBPB) OTM9MQIA CEBPB_HUMAN Increases Expression [12]
Early growth response protein 1 (EGR1) OTCP6XGZ EGR1_HUMAN Increases Expression [12]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3) OTC1UOHP ATF3_HUMAN Increases Expression [12]
C-X-C motif chemokine 2 (CXCL2) OTEJCYMY CXCL2_HUMAN Increases Expression [12]
C-X-C motif chemokine 3 (CXCL3) OTSL94KH CXCL3_HUMAN Increases Expression [12]
Endothelin-2 (EDN2) OTQ7RCPI EDN2_HUMAN Decreases Expression [12]
Tumor necrosis factor alpha-induced protein 3 (TNFAIP3) OTVLI4DD TNAP3_HUMAN Increases Expression [12]
Diamine acetyltransferase 1 (SAT1) OT52AU22 SAT1_HUMAN Increases Expression [12]
Prostaglandin G/H synthase 1 (PTGS1) OTHCRLEC PGH1_HUMAN Decreases Expression [12]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [12]
Tumor necrosis factor receptor superfamily member 5 (CD40) OT5YU2XB TNR5_HUMAN Decreases Expression [12]
Myristoylated alanine-rich C-kinase substrate (MARCKS) OT7N056G MARCS_HUMAN Increases Expression [12]
Protein EVI2B (EVI2B) OT98X1OE EVI2B_HUMAN Decreases Expression [12]
Heat shock 70 kDa protein 1-like (HSPA1L) OTC2V1K6 HS71L_HUMAN Decreases Expression [12]
Glutaredoxin-1 (GLRX) OT0QHTAR GLRX1_HUMAN Increases Expression [12]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [12]
Nicotinamide N-methyltransferase (NNMT) OTFM38GU NNMT_HUMAN Increases Expression [12]
B-cell lymphoma 6 protein (BCL6) OTQAWWO1 BCL6_HUMAN Increases Expression [12]
Regulator of G-protein signaling 2 (RGS2) OT0FSRW7 RGS2_HUMAN Increases Expression [12]
Leukemia inhibitory factor receptor (LIFR) OT36W9O5 LIFR_HUMAN Increases Expression [12]
Melanoma-associated antigen 10 (MAGEA10) OTI4KPYB MAGAA_HUMAN Decreases Expression [12]
Lysophosphatidic acid receptor 6 (LPAR6) OT4BY3W4 LPAR6_HUMAN Decreases Expression [12]
Ras GTPase-activating-like protein IQGAP1 (IQGAP1) OTZRWTGA IQGA1_HUMAN Increases Expression [12]
Retinaldehyde dehydrogenase 3 (ALDH1A3) OT1C9NKQ AL1A3_HUMAN Increases Expression [12]
Max-interacting protein 1 (MXI1) OTUQ9E0D MXI1_HUMAN Increases Expression [12]
ETS translocation variant 1 (ETV1) OT6PMJIK ETV1_HUMAN Increases Expression [12]
Glypican-3 (GPC3) OTWS8WSW GPC3_HUMAN Increases Expression [12]
Transcription initiation factor IIA subunit 1 (GTF2A1) OTWW4PN0 TF2AA_HUMAN Affects Expression [12]
Growth arrest-specific protein 1 (GAS1) OTKJXG52 GAS1_HUMAN Decreases Expression [12]
Puromycin-sensitive aminopeptidase (NPEPPS) OTMENFXR PSA_HUMAN Decreases Expression [12]
Methionine--tRNA ligase, cytoplasmic (MARS1) OTLJ6MHJ SYMC_HUMAN Increases Expression [12]
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN) OTOWDUNT PTEN_HUMAN Affects Expression [12]
Ras-related protein Rab-8A (RAB8A) OTPB54Y3 RAB8A_HUMAN Decreases Expression [12]
Lysozyme C (LYZ) OTD7H0G6 LYSC_HUMAN Decreases Expression [12]
Transforming growth factor beta-2 proprotein (TGFB2) OTC0TXEP TGFB2_HUMAN Increases Expression [12]
Large ribosomal subunit protein eL37 (RPL37) OTB6SDZ1 RL37_HUMAN Increases Expression [12]
Histone H4 (H4C1) OTB71W46 H4_HUMAN Decreases Expression [12]
C-C motif chemokine 20 (CCL20) OTUCJY4N CCL20_HUMAN Increases Expression [12]
ADP-ribosylation factor 1 (ARF1) OT5C4C3L ARF1_HUMAN Decreases Expression [12]
Nuclear factor NF-kappa-B p100 subunit (NFKB2) OTS231V7 NFKB2_HUMAN Affects Expression [12]
Methylmalonate-semialdehyde/malonate-semialdehyde dehydrogenase , mitochondrial (ALDH6A1) OT8LCZCT MMSA_HUMAN Increases Expression [12]
Pro-neuregulin-1, membrane-bound isoform (NRG1) OTZO6F1X NRG1_HUMAN Increases Expression [12]
Tyrosine-protein phosphatase non-receptor type 11 (PTPN11) OTFH9M73 PTN11_HUMAN Affects Expression [12]
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1) OTG2T749 CP24A_HUMAN Decreases Expression [12]
ATP-dependent RNA helicase A (DHX9) OT5AAOQI DHX9_HUMAN Decreases Expression [12]
Nuclear cap-binding protein subunit 1 (NCBP1) OTYBR927 NCBP1_HUMAN Increases Expression [12]
TP53-binding protein 1 (TP53BP1) OTL8879S TP53B_HUMAN Increases Expression [12]
Ankyrin-3 (ANK3) OTJ3IRBP ANK3_HUMAN Increases Expression [12]
TNF receptor-associated factor 1 (TRAF1) OTTLM5RU TRAF1_HUMAN Affects Expression [12]
PDZK1-interacting protein 1 (PDZK1IP1) OTWA6M5K PDZ1I_HUMAN Increases Expression [12]
Treacle protein (TCOF1) OT4BOYTM TCOF_HUMAN Decreases Expression [12]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Affects Expression [12]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Increases Expression [12]
Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1) OTD1KRKO DYHC1_HUMAN Decreases Expression [12]
Enhancer of filamentation 1 (NEDD9) OTGCFN4M CASL_HUMAN Increases Expression [12]
Interferon regulatory factor 3 (IRF3) OT81U8ME IRF3_HUMAN Decreases Expression [12]
FXYD domain-containing ion transport regulator 3 (FXYD3) OT9PPRHE FXYD3_HUMAN Increases Expression [12]
Ankyrin repeat domain-containing protein 1 (ANKRD1) OTHJ7JV9 ANKR1_HUMAN Increases Expression [12]
Disks large homolog 2 (DLG2) OTQ3BD8U DLG2_HUMAN Increases Expression [12]
Cysteine and glycine-rich protein 2 (CSRP2) OT4SW0HI CSRP2_HUMAN Increases Expression [12]
Cyclin-G2 (CCNG2) OTII38K2 CCNG2_HUMAN Increases Expression [12]
Golgi-associated kinase 1B (GASK1B) OT2HPHEI GAK1B_HUMAN Decreases Expression [12]
SUZ domain-containing protein 1 (SZRD1) OTJMEJWT SZRD1_HUMAN Decreases Expression [12]
Leucine-rich repeat-containing protein 28 (LRRC28) OTFTT6VN LRC28_HUMAN Increases Expression [12]
Mitochondrial basic amino acids transporter (SLC25A29) OT09PIFE S2529_HUMAN Increases Expression [12]
Equilibrative nucleobase transporter 1 (SLC43A3) OTR60ZLA S43A3_HUMAN Decreases Expression [12]
Proprotein convertase subtilisin/kexin type 9 (PCSK9) OTI0DU9Y PCSK9_HUMAN Increases Expression [12]
E3 ubiquitin-protein ligase RNF149 (RNF149) OT6SBKQV RN149_HUMAN Increases Expression [12]
F-box only protein 25 (FBXO25) OTDFA7F4 FBX25_HUMAN Increases Expression [12]
Solute carrier family 2, facilitated glucose transporter member 14 (SLC2A14) OTBFIOVY GTR14_HUMAN Increases Expression [12]
Membrane progestin receptor beta (PAQR8) OTGZ8W9F PAQR8_HUMAN Increases Expression [12]
Nuclear receptor subfamily 4 group A member 3 (NR4A3) OTPBE9R1 NR4A3_HUMAN Increases Expression [12]
La-related protein 4B (LARP4B) OT2HI0QE LAR4B_HUMAN Increases Expression [12]
Collagen triple helix repeat-containing protein 1 (CTHRC1) OTV88X2G CTHR1_HUMAN Increases Expression [12]
BTB/POZ domain-containing protein KCTD12 (KCTD12) OTPYKT4Z KCD12_HUMAN Decreases Expression [12]
Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 (MAGI1) OTMV4ASV MAGI1_HUMAN Increases Expression [12]
Sialidase-1 (NEU1) OTH9BY8Y NEUR1_HUMAN Increases Expression [12]
Galactosylceramide sulfotransferase (GAL3ST1) OTSFFZRD G3ST1_HUMAN Decreases Expression [12]
Junctional adhesion molecule C (JAM3) OTX0F9QL JAM3_HUMAN Decreases Expression [12]
SLIT and NTRK-like protein 2 (SLITRK2) OTPVI22J SLIK2_HUMAN Increases Expression [12]
Anaphase-promoting complex subunit 1 (ANAPC1) OT2YY35L APC1_HUMAN Increases Expression [12]
Anthrax toxin receptor 1 (ANTXR1) OT5W1GPC ANTR1_HUMAN Affects Expression [12]
Ras-related GTP-binding protein D (RRAGD) OTXLVWAH RRAGD_HUMAN Increases Expression [12]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Affects Expression [12]
Intersectin-2 (ITSN2) OT8S0OO8 ITSN2_HUMAN Increases Expression [12]
Probable ribosome biogenesis protein RLP24 (RSL24D1) OT6KI56F RLP24_HUMAN Increases Expression [12]
Transcription elongation factor A protein-like 9 (TCEAL9) OT4UHDB5 TCAL9_HUMAN Increases Expression [12]
Histone deacetylase 9 (HDAC9) OTO8O0LF HDAC9_HUMAN Increases Expression [12]
Phosphoserine aminotransferase (PSAT1) OTVV1YV9 SERC_HUMAN Increases Expression [12]
Chloride intracellular channel protein 4 (CLIC4) OT6KTPKD CLIC4_HUMAN Increases Expression [12]
Alpha-2-macroglobulin (A2M) OTFTX90K A2MG_HUMAN Increases Expression [13]
Pro-epidermal growth factor (EGF) OTANRJ0L EGF_HUMAN Decreases Expression [13]
Insulin (INS) OTZ85PDU INS_HUMAN Increases Expression [13]
Lymphotoxin-alpha (LTA) OTUC3S76 TNFB_HUMAN Increases Expression [13]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Expression [13]
Interferon gamma (IFNG) OTXG9JM7 IFNG_HUMAN Decreases Expression [13]
Interleukin-1 alpha (IL1A) OTPSGILV IL1A_HUMAN Decreases Expression [13]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Decreases Expression [13]
Serum amyloid P-component (APCS) OT76JZ8Z SAMP_HUMAN Decreases Expression [13]
Beta-2-glycoprotein 1 (APOH) OTFMUX6O APOH_HUMAN Increases Expression [13]
Alpha-fetoprotein (AFP) OT9GG3ZI FETA_HUMAN Decreases Expression [13]
Granulocyte-macrophage colony-stimulating factor (CSF2) OT1M7D28 CSF2_HUMAN Decreases Expression [13]
Interleukin-4 (IL4) OTOXBWAU IL4_HUMAN Decreases Expression [13]
Myeloperoxidase (MPO) OTOOXLIN PERM_HUMAN Increases Expression [13]
Endothelin-1 (EDN1) OTZCACEG EDN1_HUMAN Decreases Expression [13]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Decreases Expression [13]
Stromelysin-1 (MMP3) OTGBI74Z MMP3_HUMAN Decreases Expression [13]
Coagulation factor VII (F7) OTGNJ97M FA7_HUMAN Decreases Expression [13]
Fibroblast growth factor 2 (FGF2) OT7YUJ9F FGF2_HUMAN Increases Expression [13]
Granulocyte colony-stimulating factor (CSF3) OT9GC6TP CSF3_HUMAN Decreases Expression [13]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [13]
C-C motif chemokine 3 (CCL3) OTW2H3ND CCL3_HUMAN Increases Expression [13]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [13]
Prostatic acid phosphatase (ACP3) OTSIM0YG PPAP_HUMAN Decreases Expression [13]
Kit ligand (KITLG) OTB9AVQ4 SCF_HUMAN Decreases Expression [13]
Interleukin-10 (IL10) OTIRFRXC IL10_HUMAN Decreases Expression [13]
Brain-derived neurotrophic factor (BDNF) OTLGH7EW BDNF_HUMAN Decreases Expression [13]
CD40 ligand (CD40LG) OT75Z6A6 CD40L_HUMAN Decreases Expression [13]
Interleukin-13 (IL13) OTI4YS3Y IL13_HUMAN Increases Expression [13]
Thrombopoietin (THPO) OTO73DZ2 TPO_HUMAN Increases Expression [13]
Interleukin-15 (IL15) OTQSYWQS IL15_HUMAN Decreases Expression [13]
Leptin (LEP) OT5Q7ODW LEP_HUMAN Decreases Expression [13]
Pappalysin-1 (PAPPA) OTTTG9PG PAPP1_HUMAN Decreases Expression [13]
Pro-interleukin-16 (IL16) OTZ2MO6B IL16_HUMAN Increases Expression [13]
Adiponectin (ADIPOQ) OTNX23LE ADIPO_HUMAN Increases Expression [13]
Aldehyde dehydrogenase 1A1 (ALDH1A1) OTCUWZKB AL1A1_HUMAN Decreases Expression [30]
Neurogenic locus notch homolog protein 1 (NOTCH1) OTI1WADQ NOTC1_HUMAN Increases Expression [30]
Proto-oncogene c-Rel (REL) OTTCKMAC REL_HUMAN Decreases Expression [30]
Telomerase reverse transcriptase (TERT) OT085VVA TERT_HUMAN Decreases Activity [31]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [32]
Nuclear protein 1 (NUPR1) OT4FU8C0 NUPR1_HUMAN Decreases Expression [33]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Decreases Expression [34]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [35]
Insulin-like growth factor 1 receptor (IGF1R) OTXJIF13 IGF1R_HUMAN Decreases Expression [28]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [36]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [37]
Zinc finger protein GLI2 (GLI2) OTIRV97L GLI2_HUMAN Affects Expression [28]
Clusterin (CLU) OTQGG0JM CLUS_HUMAN Increases Expression [38]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Decreases Expression [28]
Serine/threonine-protein kinase B-raf (BRAF) OT7S81XQ BRAF_HUMAN Decreases Expression [28]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Increases Expression [36]
CD44 antigen (CD44) OT9TTJ41 CD44_HUMAN Affects Expression [26]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [39]
Insulin-like growth factor-binding protein 3 (IGFBP3) OTIX63TX IBP3_HUMAN Affects Expression [28]
Cannabinoid receptor 1 (CNR1) OTEALO6G CNR1_HUMAN Increases Expression [40]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Increases Expression [41]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Increases Phosphorylation [29]
Aryl hydrocarbon receptor nuclear translocator (ARNT) OTMSIEZY ARNT_HUMAN Increases Expression [28]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Increases Phosphorylation [29]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Increases Methylation [42]
Cannabinoid receptor 2 (CNR2) OTYP9P43 CNR2_HUMAN Increases Expression [40]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Increases Expression [43]
Breast cancer type 1 susceptibility protein (BRCA1) OT5BN6VH BRCA1_HUMAN Increases Expression [28]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Decreases Activity [44]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [45]
Proliferation marker protein Ki-67 (MKI67) OTA8N1QI KI67_HUMAN Decreases Expression [32]
Dual specificity mitogen-activated protein kinase kinase 3 (MAP2K3) OTI2OREX MP2K3_HUMAN Increases Phosphorylation [46]
Transcription factor SOX-2 (SOX2) OTFAWCAU SOX2_HUMAN Increases Expression [43]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Increases Phosphorylation [47]
Dual specificity mitogen-activated protein kinase kinase 6 (MAP2K6) OTK13JKC MP2K6_HUMAN Increases Phosphorylation [46]
Serine/threonine-protein kinase PLK1 (PLK1) OTRZX45T PLK1_HUMAN Decreases Expression [28]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [45]
BH3-interacting domain death agonist (BID) OTOSHSHU BID_HUMAN Increases Cleavage [48]
C-X-C chemokine receptor type 4 (CXCR4) OTUFSBX2 CXCR4_HUMAN Affects Expression [28]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Decreases Expression [28]
POU domain, class 5, transcription factor 1 (POU5F1) OTDHHN7O PO5F1_HUMAN Decreases Expression [26]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Increases Expression [49]
Regenerating islet-derived protein 3-alpha (REG3A) OT0BVQRB REG3A_HUMAN Decreases Expression [47]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [29]
Protein patched homolog 1 (PTCH1) OTMG07H5 PTC1_HUMAN Affects Expression [28]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [45]
Sonic hedgehog protein (SHH) OTOG2BXF SHH_HUMAN Decreases Expression [28]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Increases Expression [36]
Tumor protein p53-inducible nuclear protein 1 (TP53INP1) OT2363Z9 T53I1_HUMAN Increases Expression [47]
Protein smoothened (SMO) OTXXE208 SMO_HUMAN Increases Expression [43]
Homeobox protein NANOG (NANOG) OTUEY1FM NANOG_HUMAN Decreases Expression [43]
Axin-2 (AXIN2) OTRMGQNU AXIN2_HUMAN Affects Expression [28]
3',5'-cyclic-AMP phosphodiesterase 4D (PDE4D) OT1RWFV0 PDE4D_HUMAN Increases ADR [50]
Focal adhesion kinase 1 (PTK2) OT3Q1JDY FAK1_HUMAN Decreases Response To Substance [51]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Affects Response To Substance [52]
Splicing factor 45 (RBM17) OT9ROJCL SPF45_HUMAN Decreases Response To Substance [53]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Affects Response To Substance [54]
Neuropilin-1 (NRP1) OTCGULYV NRP1_HUMAN Decreases Response To Substance [55]
Oxysterol-binding protein 2 (OSBP2) OTDGLB4J OSBP2_HUMAN Increases ADR [50]
Proto-oncogene tyrosine-protein kinase Src (SRC) OTETYX40 SRC_HUMAN Decreases Response To Substance [56]
Equilibrative nucleoside transporter 3 (SLC29A3) OTGLX8XU S29A3_HUMAN Affects Transport [57]
Probable ATP-dependent RNA helicase DDX53 (DDX53) OTHK3EGZ DDX53_HUMAN Affects Response To Substance [58]
Amphiregulin (AREG) OTJFOR67 AREG_HUMAN Decreases Response To Substance [59]
Pyruvate kinase PKM (PKM) OTLHHMC2 KPYM_HUMAN Affects Response To Substance [32]
Equilibrative nucleoside transporter 1 (SLC29A1) OTLOOZZS S29A1_HUMAN Increases Response To Substance [60]
Alpha-protein kinase 3 (ALPK3) OTLUYSMO ALPK3_HUMAN Increases ADR [50]
Transcription factor AP-2-alpha (TFAP2A) OTMYT3NK AP2A_HUMAN Increases Response To Substance [61]
Death-associated protein kinase 1 (DAPK1) OTNCNUCO DAPK1_HUMAN Increases ADR [62]
Cytochrome c oxidase subunit 3 (COX3) OTNNGBYJ COX3_HUMAN Decreases Response To Substance [63]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Decreases Response To Substance [64]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Increases ADR [65]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Affects Response To Substance [66]
3-phosphoinositide-dependent protein kinase 1 (PDPK1) OTT09ZVP PDPK1_HUMAN Decreases Response To Substance [67]
Nucleophosmin (NPM1) OTTBYYT0 NPM_HUMAN Decreases Response To Substance [68]
Serine/threonine-protein kinase SMG1 (SMG1) OTTS3SXE SMG1_HUMAN Decreases Response To Substance [69]
ATP-dependent DNA helicase PIF1 (PIF1) OTUHKKVP PIF1_HUMAN Decreases Response To Substance [39]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Decreases Response To Substance [70]
Ribonucleoside-diphosphate reductase large subunit (RRM1) OTXGQOR9 RIR1_HUMAN Increases ADR [71]
Olfactory receptor 4D6 (OR4D6) OTXJKUT1 OR4D6_HUMAN Affects Response To Substance [58]
PDZ domain-containing protein GIPC1 (GIPC1) OTXLVCPJ GIPC1_HUMAN Affects Response To Substance [72]
Integrin-linked protein kinase (ILK) OTYG2FD1 ILK_HUMAN Affects Response To Substance [52]
Poly polymerase 2 (PARP2) OTYL81ZI PARP2_HUMAN Decreases Response To Substance [73]
------------------------------------------------------------------------------------
⏷ Show the Full List of 244 DOT(s)
Indication(s) of Imatinib
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [3]
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive N.A. Approved [6]
Choroidal neovascularization 9B76 Approved [6]
Chronic eosinophilic leukemia N.A. Approved [6]
Chronic myelogenous leukaemia 2A20.0 Approved [7]
Chronic myeloid leukaemia 2A20 Approved [8]
Dermatofibrosarcoma protuberans N.A. Approved [6]
Gastrointestinal stromal tumour 2B5B Approved [6]
Leukemia N.A. Approved [6]
Malignant peripheral nerve sheath tumor N.A. Approved [6]
Myeloproliferative neoplasm 2A20 Approved [6]
Pulmonary hypertension BB01 Approved [6]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [9]
Intestinal cancer 2C0Z Phase 3 [7]
Lung cancer 2C25.0 Phase 2 [7]
Idiopathic hypereosinophilic syndrome N.A. Investigative [6]
Middle East Respiratory Syndrome (MERS) 1D64 Investigative [10]
Scleroderma 4A42 Investigative [6]
Severe acute respiratory syndrome (SARS) 1D65 Investigative [10]
Systemic mastocytosis 2A21.0 Investigative [11]
Imatinib Interacts with 5 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Mcl-1 messenger RNA (MCL-1 mRNA) TTN6ORK MCL1_HUMAN . [11]
Fusion protein Bcr-Abl (Bcr-Abl) TTS7G69 BCR_HUMAN-ABL1_HUMAN Inhibitor [77]
Platelet-derived growth factor receptor (PDGFR) TTI2WET NOUNIPROTAC Inhibitor [77]
Tyrosine-protein kinase Kit (KIT) TTX41N9 KIT_HUMAN Inhibitor [77]
HUMAN fusion protein Bcr-Abl (Bcr-Abl) TTE63HY BCR_HUMAN/ABL1_HUMAN Inhibitor [10]
------------------------------------------------------------------------------------
Imatinib Interacts with 6 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [78]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [79]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [80]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [81]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [82]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [80]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DTP(s)
Imatinib Interacts with 8 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [83]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [84]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [85]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [86]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [87]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [88]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [89]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Metabolism [85]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DME(s)
Imatinib Interacts with 95 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Methylation [90]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Decreases Methylation [90]
Cytochrome P450 3A7 (CYP3A7) OTTCDHHM CP3A7_HUMAN Decreases Methylation [90]
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Decreases Methylation [90]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Increases Expression [91]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [91]
Aldehyde dehydrogenase, mitochondrial (ALDH2) OTKJ9I3N ALDH2_HUMAN Decreases Expression [92]
Eukaryotic translation initiation factor 4E (EIF4E) OTDAWNLA IF4E_HUMAN Decreases Expression [92]
Fructose-bisphosphate aldolase C (ALDOC) OTEC13I5 ALDOC_HUMAN Decreases Expression [92]
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial (PDHB) OT2NHE5E ODPB_HUMAN Decreases Expression [92]
Cyclin-dependent kinase 4 (CDK4) OT7EP05T CDK4_HUMAN Decreases Expression [92]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Decreases Expression [92]
Ribosomal protein S6 kinase beta-1 (RPS6KB1) OTAELNGX KS6B1_HUMAN Decreases Expression [92]
Eukaryotic translation initiation factor 4B (EIF4B) OTE8TXA8 IF4B_HUMAN Decreases Expression [92]
Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1) OT5BZ1J9 P85A_HUMAN Decreases Expression [92]
G1/S-specific cyclin-D3 (CCND3) OTNKPQ22 CCND3_HUMAN Decreases Expression [92]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Expression [92]
Hexokinase-4 (GCK) OTR3Q0NN HXK4_HUMAN Decreases Expression [92]
Serine/threonine-protein kinase mTOR (MTOR) OTHH8KU7 MTOR_HUMAN Decreases Expression [92]
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform (PPP2CA) OT83PT85 PP2AA_HUMAN Increases Expression [92]
Eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1) OTHBQVD5 4EBP1_HUMAN Decreases Expression [92]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [93]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Decreases Expression [94]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [95]
Autophagy-related protein 13 (ATG13) OTYMHNEJ ATG13_HUMAN Increases Phosphorylation [74]
Platelet-derived growth factor subunit B (PDGFB) OTMFMFC3 PDGFB_HUMAN Decreases Expression [96]
Interferon gamma (IFNG) OTXG9JM7 IFNG_HUMAN Increases Expression [97]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Secretion [98]
Keratin, type I cytoskeletal 14 (KRT14) OTUVZ1DW K1C14_HUMAN Increases Expression [99]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [100]
Heat shock protein beta-1 (HSPB1) OTHFZ8ED HSPB1_HUMAN Increases Expression [95]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Activity [101]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Increases Expression [95]
Tyrosine-protein kinase Lck (LCK) OT883FG9 LCK_HUMAN Decreases Phosphorylation [102]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Expression [97]
Cathepsin B (CTSB) OTP9G5QB CATB_HUMAN Increases Expression [74]
Proto-oncogene tyrosine-protein kinase receptor Ret (RET) OTLU040A RET_HUMAN Decreases Phosphorylation [103]
ATP-dependent 6-phosphofructokinase, muscle type (PFKM) OT1QY9JM PFKAM_HUMAN Decreases Expression [104]
Platelet-derived growth factor receptor beta (PDGFRB) OTYSNK9Q PGFRB_HUMAN Decreases Expression [96]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [105]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [95]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [106]
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1) OTA675TJ GTR1_HUMAN Decreases Expression [100]
Breakpoint cluster region protein (BCR) OTCN76C1 BCR_HUMAN Decreases Activity [76]
Lysosome-associated membrane glycoprotein 1 (LAMP1) OTYE92QY LAMP1_HUMAN Increases Expression [74]
Ornithine decarboxylase (ODC1) OTNDAGRR DCOR_HUMAN Increases Expression [95]
Keratin, type II cytoskeletal 5 (KRT5) OTVGI9HT K2C5_HUMAN Increases Expression [99]
Tissue factor (F3) OT3MSU3B TF_HUMAN Increases Expression [107]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [108]
Platelet-derived growth factor receptor alpha (PDGFRA) OTDJXUCN PGFRA_HUMAN Decreases Expression [96]
CCAAT/enhancer-binding protein beta (CEBPB) OTM9MQIA CEBPB_HUMAN Increases Expression [95]
Histidine decarboxylase (HDC) OT4WA5YQ DCHS_HUMAN Decreases Expression [109]
Transcription factor EB (TFEB) OTJUJJQY TFEB_HUMAN Affects Localization [74]
Fibroblast growth factor receptor 3 (FGFR3) OTSAXDIL FGFR3_HUMAN Decreases Expression [110]
Insulin-like growth factor-binding protein 4 (IGFBP4) OT2HZRBD IBP4_HUMAN Increases Expression [95]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Increases Secretion [111]
Interleukin-4 receptor subunit alpha (IL4R) OTTXOTCW IL4RA_HUMAN Increases Expression [95]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Decreases Expression [97]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Increases Phosphorylation [95]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Phosphorylation [102]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Phosphorylation [102]
Caspase-1 (CASP1) OTZ3YQFU CASP1_HUMAN Increases Cleavage [98]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Decreases Expression [112]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [113]
Crk-like protein (CRKL) OTOYSD1R CRKL_HUMAN Decreases Phosphorylation [114]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Increases Phosphorylation [74]
Hexokinase-2 (HK2) OTC0GCQO HXK2_HUMAN Decreases Expression [104]
Small ribosomal subunit protein eS6 (RPS6) OTT4D1LN RS6_HUMAN Decreases Phosphorylation [74]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Increases Expression [95]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Decreases Expression [112]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [106]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [115]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Expression [105]
Forkhead box protein M1 (FOXM1) OT5887KR FOXM1_HUMAN Decreases Expression [112]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [116]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Increases Expression [74]
Beclin-1 (BECN1) OT4X293M BECN1_HUMAN Increases Expression [74]
Nuclear receptor subfamily 0 group B member 2 (NR0B2) OT7UVICX NR0B2_HUMAN Increases Expression [117]
NGFI-A-binding protein 2 (NAB2) OTG4BDF3 NAB2_HUMAN Increases Expression [95]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Decreases Expression [118]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Activity [101]
TRAF family member-associated NF-kappa-B activator (TANK) OTZSGFIK TANK_HUMAN Increases Expression [95]
NACHT, LRR and PYD domains-containing protein 3 (NLRP3) OTZM6MHU NLRP3_HUMAN Increases Expression [98]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Increases Activity [117]
Docking protein 1 (DOK1) OTGVRLW6 DOK1_HUMAN Decreases Phosphorylation [119]
Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B) OTUYHB84 MLP3B_HUMAN Increases Expression [74]
Transcription factor SOX-17 (SOX17) OT9H4WWE SOX17_HUMAN Decreases Localization [120]
V-type proton ATPase subunit H (ATP6V1H) OTX17GQ9 VATH_HUMAN Increases Expression [74]
Tyrosine-protein kinase ABL1 (ABL1) OT09YVXH ABL1_HUMAN Increases Response To Substance [121]
LYR motif-containing protein 9 (LYRM9) OT1MILTK LYRM9_HUMAN Affects Response To Substance [122]
Leptin (LEP) OT5Q7ODW LEP_HUMAN Increases ADR [65]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Response To Substance [123]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Response To Substance [124]
Tyrosine-protein kinase Lyn (LYN) OTP686K2 LYN_HUMAN Decreases Response To Substance [114]
Serine/threonine-protein kinase PLK1 (PLK1) OTRZX45T PLK1_HUMAN Increases Response To Substance [105]
------------------------------------------------------------------------------------
⏷ Show the Full List of 95 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Mesothelioma, Malignant DCV773C N. A. Phase 2 [125]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01048320) Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer
2 Gemcitabine FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4793).
5 Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93.
6 Imatinib FDA Label
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5687).
8 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 078340.
9 ClinicalTrials.gov (NCT04356495) Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19). U.S. National Institutes of Health.
10 Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
11 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
12 Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat. 2007 Apr;102(2):157-72.
13 Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer. 2010 Jun 29;103(1):52-60.
14 Gemcitabine induces the VMP1-mediated autophagy pathway to promote apoptotic death in human pancreatic cancer cells. Pancreatology. 2010;10(1):19-26. doi: 10.1159/000264680. Epub 2010 Mar 19.
15 XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics. Pancreas. 2006 Apr;32(3):288-96. doi: 10.1097/01.mpa.0000218314.67111.fb.
16 Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer. 2008 Sep 2;99(5):760-7. doi: 10.1038/sj.bjc.6604528.
17 14-3-3 regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression. Oncotarget. 2016 Apr 5;7(14):17726-36. doi: 10.18632/oncotarget.7394.
18 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
19 Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer. 2003 Jun 16;88(12):1963-70.
20 Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia. 2010 Sep;12(9):740-7.
21 Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers (Basel). 2017 Nov 16;9(11).
22 Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. Br J Clin Pharmacol. 2011 Mar;71(3):437-44.
23 Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab Dispos. 2008 Sep;36(9):1951-9.
24 Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017 Sep 15;357(6356):1156-1160.
25 Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. FEBS Open Bio. 2015 Aug 3;5:634-9.
26 Deregulation of the CD44-NANOG-MDR1 associated chemoresistance pathways of breast cancer stem cells potentiates the anti-cancer effect of Kaempferol in synergism with Verapamil. Toxicol Appl Pharmacol. 2022 Feb 15;437:115887. doi: 10.1016/j.taap.2022.115887. Epub 2022 Jan 19.
27 Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis. Oncol Rep. 2007 Sep;18(3):523-9.
28 A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther. 2010 Feb;9(2):311-8. doi: 10.1158/1535-7163.MCT-09-0693. Epub 2010 Jan 26.
29 Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol. 2004 Oct 19;502(3):169-83. doi: 10.1016/j.ejphar.2004.09.006.
30 Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther. 2011 Jan;19(1):188-95.
31 Antagonistic interactions between gemcitabine and 5-fluorouracil in the human pancreatic carcinoma cell line Capan-2. Cancer Biol Ther. 2006 Oct;5(10):1294-303. doi: 10.4161/cbt.5.10.3152. Epub 2006 Oct 4.
32 Targeting PKM2 improves the gemcitabine sensitivity of intrahepatic cholangiocarcinoma cells via inhibiting -catenin signaling pathway. Chem Biol Interact. 2024 Jan 5;387:110816. doi: 10.1016/j.cbi.2023.110816. Epub 2023 Nov 22.
33 p8 is a new target of gemcitabine in pancreatic cancer cells. Clin Cancer Res. 2006 Jan 1;12(1):235-41. doi: 10.1158/1078-0432.CCR-05-1700.
34 The anthelmintic drug niclosamide induces GSK--mediated -catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression. Cell Death Dis. 2022 Feb 3;13(2):112. doi: 10.1038/s41419-022-04573-7.
35 High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter. Carcinogenesis. 2002 Jun;23(6):949-57. doi: 10.1093/carcin/23.6.949.
36 CASC9 potentiates gemcitabine resistance in pancreatic cancer by reciprocally activating NRF2 and the NF-B signaling pathway. Cell Biol Toxicol. 2023 Aug;39(4):1549-1560. doi: 10.1007/s10565-022-09746-w. Epub 2022 Aug 1.
37 Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene. 2007 May 17;26(23):3431-9. doi: 10.1038/sj.onc.1210129. Epub 2006 Dec 4.
38 Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin. BJU Int. 2009 Feb;103(3):384-90. doi: 10.1111/j.1464-410X.2008.08098.x. Epub 2008 Oct 24.
39 Petite Integration Factor 1 knockdown enhances gemcitabine sensitivity in pancreatic cancer cells via increasing DNA damage. J Appl Toxicol. 2023 Oct;43(10):1522-1532. doi: 10.1002/jat.4494. Epub 2023 May 16.
40 Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis. 2011 Apr 28;2(4):e152. doi: 10.1038/cddis.2011.36.
41 Gemcitabine-induced apoptosis in 5637 cell line: an in-vitro model for high-risk superficial bladder cancer. Anticancer Drugs. 2007 Feb;18(2):179-85. doi: 10.1097/CAD.0b013e328010ef47.
42 Reversible epigenetic regulation of 14-3-3 expression in acquired gemcitabine resistance by uhrf1 and DNA methyltransferase 1. Mol Pharmacol. 2014 Nov;86(5):561-9. doi: 10.1124/mol.114.092544. Epub 2014 Sep 4.
43 Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44. doi: 10.1073/pnas.1424171112. Epub 2015 Jan 20.
44 EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer. PLoS One. 2012;7(2):e31067. doi: 10.1371/journal.pone.0031067. Epub 2012 Feb 13.
45 Caspase activation is required for gemcitabine activity in multiple myeloma cell lines. Mol Cancer Ther. 2002 Nov;1(13):1221-7.
46 Involvement of p38 mitogen-activated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cells. Biochem Biophys Res Commun. 2004 Mar 26;316(1):71-7. doi: 10.1016/j.bbrc.2004.02.017.
47 Effect of gemcitabine on the expression of apoptosis-related genes in human pancreatic cancer cells. World J Gastroenterol. 2006 Mar 14;12(10):1597-602. doi: 10.3748/wjg.v12.i10.1597.
48 Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer. 2004 Mar 20;109(2):182-8. doi: 10.1002/ijc.11679.
49 Gemcitabine combined with gum mastic causes potent growth inhibition and apoptosis of pancreatic cancer cells. Acta Pharmacol Sin. 2010 Jun;31(6):741-5. doi: 10.1038/aps.2010.54.
50 Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug;104(8):1074-82. doi: 10.1111/cas.12186. Epub 2013 Jun 10.
51 RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun. 2003 Nov 21;311(3):786-92. doi: 10.1016/j.bbrc.2003.10.060.
52 RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res. 2005 May 1;11(9):3433-8. doi: 10.1158/1078-0432.CCR-04-1510.
53 Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res. 2005 Aug 1;65(15):6593-600. doi: 10.1158/0008-5472.CAN-03-3675.
54 Effect of antisense hypoxia-inducible factor 1alpha on progression, metastasis, and chemosensitivity of pancreatic cancer. Pancreas. 2006 Apr;32(3):297-305. doi: 10.1097/00006676-200604000-00010.
55 Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J Cancer. 2005 Jul 25;93(2):233-41. doi: 10.1038/sj.bjc.6602663.
56 Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res. 2004 Apr 1;10(7):2307-18.
57 Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G910-22. doi: 10.1152/ajpgi.90672.2008. Epub 2009 Jan 22.
58 Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities. Clin Cancer Res. 2016 Jan 15;22(2):366-73. doi: 10.1158/1078-0432.CCR-15-0964. Epub 2015 Sep 16.
59 Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. Cancer Sci. 2010 Nov;101(11):2351-60. doi: 10.1111/j.1349-7006.2010.01671.x.
60 Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. Lab Invest. 2008 Jul;88(7):773-84. doi: 10.1038/labinvest.2008.40. Epub 2008 May 19.
61 Increased expression of transcription factor TFAP2 correlates with chemosensitivity in advanced bladder cancer. BMC Cancer. 2011 Apr 14;11:135. doi: 10.1186/1471-2407-11-135.
62 A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy. Pharmacogenet Genomics. 2012 Apr;22(4):229-35. doi: 10.1097/FPC.0b013e32834e9eba.
63 An increase of cytochrome C oxidase mediated disruption of gemcitabine incorporation into DNA in a resistant KB clone. Biochem Pharmacol. 2007 Jun 15;73(12):1927-38. doi: 10.1016/j.bcp.2007.03.014. Epub 2007 Mar 20.
64 Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol. 2011 Sep;122(3):641-7. doi: 10.1016/j.ygyno.2011.05.003. Epub 2011 Jun 8.
65 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
66 Triplex-forming oligonucleotides targeting c-MYC potentiate the anti-tumor activity of gemcitabine in a mouse model of human cancer. Mol Carcinog. 2014 Sep;53(9):744-52. doi: 10.1002/mc.22026. Epub 2013 May 16.
67 Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. Mol Pharmacol. 2006 Sep;70(3):1045-52. doi: 10.1124/mol.106.023333. Epub 2006 Jun 16.
68 Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
69 [Effect of inhibiting the expression of hSMG-1 on chemosensitivity of human non-small cell lung cancer H1299 cells]. Zhonghua Yi Xue Za Zhi. 2011 Mar 1;91(8):554-9.
70 A novel 3-dimensional culture system uncovers growth stimulatory actions by TGF in pancreatic cancer cells. Cancer Biol Ther. 2011 Aug 1;12(3):198-207. doi: 10.4161/cbt.12.3.15979. Epub 2011 Aug 1.
71 An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. Oncologist. 2007 Jun;12(6):622-30. doi: 10.1634/theoncologist.12-6-622.
72 GAIP interacting protein C-terminus regulates autophagy and exosome biogenesis of pancreatic cancer through metabolic pathways. PLoS One. 2014 Dec 3;9(12):e114409. doi: 10.1371/journal.pone.0114409. eCollection 2014.
73 Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 2010 Oct 15;70(20):7970-80. doi: 10.1158/0008-5472.CAN-09-4521. Epub 2010 Aug 26.
74 Imatinib disturbs lysosomal function and morphology and impairs the activity of mTORC1 in human hepatocyte cell lines. Food Chem Toxicol. 2022 Apr;162:112869. doi: 10.1016/j.fct.2022.112869. Epub 2022 Feb 16.
75 Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3532-40. doi: 10.1158/1078-0432.CCR-05-1778.
76 Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer. 2004 Sep 1;101(5):979-88. doi: 10.1002/cncr.20457.
77 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
78 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
79 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
80 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
81 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
82 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
83 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
84 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
85 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
86 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
87 Drug Interactions Flockhart Table
88 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
89 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
90 Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol. 2010 Nov;161(5):1059-69. doi: 10.1111/j.1476-5381.2010.00946.x.
91 Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.
92 A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3378-83.
93 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
94 Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-B inactivation. Toxicol In Vitro. 2012 Apr;26(3):396-405.
95 Effects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitro. PLoS One. 2011;6(9):e24831. doi: 10.1371/journal.pone.0024831. Epub 2011 Sep 14.
96 Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. Cancer. 2005 May 1;103(9):1800-9. doi: 10.1002/cncr.20973.
97 Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis?. Clin Exp Immunol. 2008 Mar;151(3):391-8. doi: 10.1111/j.1365-2249.2007.03572.x. Epub 2008 Jan 10.
98 Imatinib-induced hepatotoxicity via oxidative stress and activation of NLRP3 inflammasome: an in vitro and in vivo study. Arch Toxicol. 2022 Apr;96(4):1075-1087. doi: 10.1007/s00204-022-03245-x. Epub 2022 Feb 22.
99 Oral lichenoid eruption secondary to imatinib (Glivec). J Dermatolog Treat. 2004 Jul;15(4):253-5. doi: 10.1080/09546630410015556.
100 AMP-activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR-ABL protein in CML cells. Cancer Sci. 2021 Jan;112(1):194-204. doi: 10.1111/cas.14698. Epub 2020 Nov 16.
101 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
102 Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood. 2004 Aug 15;104(4):1094-9. doi: 10.1182/blood-2003-12-4266. Epub 2004 Apr 20.
103 Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res. 2005 Feb 1;11(3):1336-41.
104 Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells. Chem Biol Interact. 2015 May 25;233:147-56. doi: 10.1016/j.cbi.2015.03.028. Epub 2015 Apr 8.
105 Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells. Oncotarget. 2015 Aug 21;6(24):20231-40. doi: 10.18632/oncotarget.4047.
106 Saikosaponin D disrupts platelet-derived growth factor- receptor/p38 pathway leading to mitochondrial apoptosis in human LO2 hepatocyte cells: a potential mechanism of hepatotoxicity. Chem Biol Interact. 2013 Oct 25;206(1):76-82. doi: 10.1016/j.cbi.2013.08.006. Epub 2013 Aug 28.
107 Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects. Int J Mol Sci. 2015 Jan 5;16(1):1008-29. doi: 10.3390/ijms16011008.
108 Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. Cancer Res. 2010 Jan 1;70(1):150-9. doi: 10.1158/0008-5472.CAN-09-1449. Epub 2009 Dec 22.
109 The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells. Blood. 2006 Nov 15;108(10):3538-47. doi: 10.1182/blood-2005-12-028456. Epub 2006 Jul 18.
110 Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia. Leukemia. 2003 Dec;17(12):2418-25. doi: 10.1038/sj.leu.2403152.
111 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
112 Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Clin Cancer Res. 2017 Feb 1;23(3):789-803. doi: 10.1158/1078-0432.CCR-16-0226. Epub 2016 Aug 4.
113 In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol. 2002 Jul;30(7):729-37. doi: 10.1016/s0301-472x(02)00836-6.
114 Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. Eur J Haematol. 2007 May;78(5):417-31. doi: 10.1111/j.1600-0609.2007.00835.x.
115 The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol Pharmacol. 2001 Mar;59(3):453-61. doi: 10.1124/mol.59.3.453.
116 Downregulation of hERG channel expression by tyrosine kinase inhibitors nilotinib and vandetanib predominantly contributes to arrhythmogenesis. Toxicol Lett. 2022 Jul 15;365:11-23. doi: 10.1016/j.toxlet.2022.06.001. Epub 2022 Jun 6.
117 Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Biochem Pharmacol. 2012 Jun 15;83(12):1674-81. doi: 10.1016/j.bcp.2012.02.027. Epub 2012 Mar 7.
118 A new strategy for the rapid identification and validation of direct toxicity targets of psoralen-induced hepatotoxicity. Toxicol Lett. 2022 Jun 15;363:11-26. doi: 10.1016/j.toxlet.2022.05.002. Epub 2022 May 18.
119 Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res. 2009 May 1;69(9):3927-36. doi: 10.1158/0008-5472.CAN-08-2978. Epub 2009 Apr 14.
120 A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci. 2014 Jan;137(1):76-90. doi: 10.1093/toxsci/kft239. Epub 2013 Oct 23.
121 Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem. 2004 Jul;50(7):1205-13. doi: 10.1373/clinchem.2004.031112. Epub 2004 Apr 23.
122 Identification of Genes That Modulate Susceptibility to Formaldehyde and Imatinib by Functional Genomic Screening in Human Haploid KBM7 Cells. Toxicol Sci. 2016 May;151(1):10-22. doi: 10.1093/toxsci/kfw032. Epub 2016 Mar 22.
123 Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res. 2005 Sep 15;65(18):8224-32. doi: 10.1158/0008-5472.CAN-05-0303.
124 Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur J Cancer. 2009 Jul;45(10):1877-89. doi: 10.1016/j.ejca.2009.04.005. Epub 2009 May 4.
125 ClinicalTrials.gov (NCT02303899) Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma